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Abstract
This study investigates the regulation of cAMP-stimulated casein secretion in rat mammary explants by cAMP phosphodiesterase (cAMP-
PDE) activity. cAMP-PDE activity of the lactating rat mammary gland is shown to be provided by three families, types II, III and IV. In
mammary explants, general inhibition of the cAMP-PDE activity significantly increased the rate of cAMP-stimulated casein secretion. This
effect could be mimicked using the type-IV specific inhibitor rolipram but not by the specific, or combined, inhibition of the type II and type III
activity. Only type IVactivity significantly affected intracellular accumulation of cAMP whereas all three cAMP-PDE activities were shown to
influence the PKA activation ratio in cells. RtPCR analysis showed that the mammary gland apparently expresses just three type IV isozymes,
RNPDE4A5, RNPDE4A8 and RNPDE4D3. A specific role for type IV cAMP-PDE activity in the regulation of casein secretion is suggested
and possible mechanisms for the effects of PDEIV activity discussed. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
During lactation, mammary epithelial cells synthesise and
secrete in a polarised manner, large amounts of the major
milk proteins, caseins. Following synthesis, the caseins are
transported through the secretory pathway, packaged into
secretory vesicles and moved to the apical plasma membrane
[1]. Here the majority of the vesicles are released by
exocytosis though a small proportion is stored just beneath
the plasma membrane for later release by a calcium-regu-
lated process [2]. These two processes are referred to as basal
constitutive secretion (calcium-independent) and triggered
secretion (calcium-dependent). While we understand the
fundamental principles of the basal (Ca2+ -independent)
secretory pathway, much remains to be learned about the
factors that regulate this constitutive passage of caseins
through the mammary cell secretory apparatus.
Early in vitro work in rabbit mammary tissue did show
acute regulation of the basal secretory pathway by prolactin
[3]. It has also been suggested that oxytocin might increase
constitutive casein secretion by causing contraction of the
myoepithelial cells [4]. A role for the cyclic AMP signalling
system was first suggested as early as 1975 and several
reports using mammary tissue from different species show
that cAMP-elevating agents stimulate the rate of casein
secretion [5–7]. More recent work has significantly sub-
stantiated the evidence for a cAMP-mediated pathway show-
ing that PKA mediates the tonic positive regulation of this
process [8]. These authors showed that agents that caused the
activation of PKA increased the rate of secretion of newly
synthesised caseins and, conversely, inhibition of PKA
activity slowed casein secretion.
In the cell, activation of PKA requires a critical threshold
concentration of cAMP to be achieved. At any given time,
the net intracellular concentration of cAMP is the conse-
quence of the competing rates of its synthesis and its de-
gradation. Cyclic AMP phosphodiesterases (cAMP-PDEs)
provide the sole means of degradation of cAMP within the
cell. Hence, cAMP-PDEs play a critical role in the regulation
of intracellular cAMP concentrations and so may provide a
point of regulation of cAMP-mediated processes. cAMP-
PDEs are a complex family of enzymes and over 30 indi-
vidual isozymes have now been identified [9]. These iso-
zymes are expressed in a cell- and tissue-specific manner,
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differ in their catalytic and regulatory properties and may be
targeted to discrete subcellular localisations [9,10]. This
complexity is thought to allow for dynamic cell-specific
controls on cAMP levels and hence cAMP-mediated pro-
cesses [10]. Indeed, individual cAMP-PDE isozyme activ-
ities within a cell have been shown to be important in the
control of a variety of physiological processes. These include
PDE3 mediating the antilipolytic effect of insulin [11], PDE4
activity negatively regulating the secretion of gonadotropin-
releasing hormone from neuronal cells [12], and in mesan-
gial cells, compartmentalisation of the cAMP signalling
pathway by PDE activity, such that PDE3 regulates mito-
genesis but PDE4 regulates superoxidation [13].
In lactating rat mammary epithelial cells, early work
indicated that the mammary gland contains at least two
forms of cAMP-PDE, a cGMP-stimulated low-affinity cyclic
nucleotide PDE and a high-affinity cAMP-specific PDE
[14]. From in vitro experiments using acini, it was also
suggested that the mammary gland contains cAMP-PDE
activity subject to regulation by insulin [15]. It is apparent
that the cAMP-PDE activity of the rat mammary gland
profoundly influences the intracellular accumulation of
cAMP in response to cAMP-elevating agents. Whereas
forskolin or adrenergic reagents alone cause just a two-fold
increase in intracellular cAMP levels in acini in vitro, a 20-
fold increase can be achieved if the PDE activity is simulta-
neously inhibited [16]. However, whereas cAMP itself has
been implicated in the morphogenesis [17], mitogenesis [17]
and apoptosis [18] of mammary tissue, as well as in the
regulation of mammary gland casein secretion [8] and lipo-
genesis [19], the physiological role of cAMP-PDEs in the
mammary gland remains to be determined.
Given the influence of cAMP-PDE activity on cAMP
levels in the mammary gland, it was hypothesised that
mammary gland cAMP-PDE activity may act to negatively
regulate casein secretion by affecting levels of cAMP and the
activation status of PKA. Therefore, in this study, the role of
cAMP-PDEs in the regulation of casein secretion has been
investigated. Using modern biochemical and molecular bio-
logical approaches, the individual PDE families and PDE
isozymes expressed in the rat mammary gland have been
identified. A specific role for the PDE4 family in the
regulation of cAMP-stimulated casein secretion is reported.
2. Materials and methods
2.1. Materials
Unless otherwise stated, all reagents were supplied by
Sigma Chemical Company (Poole, Dorset, UK), BDH
(Glasgow, Scotland, UK) and Fisher Scientific, (Loughbor-
ough, Leics, UK). Radiochemicals and incubation media
were from ICN Pharmaceuticals (Basingstoke, Hants, UK).
Except where indicated, all operations and experiments were
at 37 jC under an atmosphere of 95%O2:5%CO2. All buffers
and incubation media were pregassed for 15 min with O2/
CO2 (95:5%). Shaking water baths were set at 180 strokes/
min.
2.2. Animals
Wistar rats were maintained on a standard chow diet
(Labsure irradiated CRMdiet, Labsure, Poole, UK) andwater
ad libitum. All animals were in their first pregnancy and at
day 10 or 11 of lactation. The number of pups per mother was
adjusted to 10 within 24 h of birth. Ethical aspects of animal
care were in compliance with applicable guidelines and
licensing requirements administered by the UKHome Office.
2.3. Preparation of mammary explants and acini
On the day of the experiment, mammary tissue was
routinely removed from the animal between 09:00 and
10:00 into 20ml of KRBG buffer (KREBS buffer as specified
by Krebs and Henseleit [20] modified to contain 5 mM
glucose and 1.2 mM CaCl2). The tissue was coarsely cut,
washed with KRBG and chopped into tiny explants using a
multi-blade chopper. Acini were prepared by suspending
explants in 30 ml of digestion medium (30 ml of KRBG
containing 600mg of dialysed fatty acid-free fraction VBSA,
1500 mg of dialysed Ficoll 400 and 40 mg of Collagenase
{type CLS 3 from Worthington Biochemical Corporation,
Lakewood, NJ, USA}) in a 250-ml conical flask for 60 min
with shaking. The resulting digest was strained through a 400
AM nylon filter, centrifuged at 1000 g for 15 s, washed
three times in KRBG containing 2% Ficoll and finally sus-
pended in KRBG containing 2% Ficoll and 4% BSA.
2.4. Metabolic pulse-chase labelling of newly synthesised
protein and measurement of casein secretion
Explants prepared from approximately 3 g of tissue were
washed, radiolabelled, and the labelling reaction quenched
as described by Clegg et al. [8]. Radiolabelling was per-
formed for 3 min using 500 ACi of TRAN35S-labelk in 10
ml RPMI-1640 (lacking methionine, cysteine and cystine).
Unincorporated precursor was removed by washing and the
explants suspended in 10 ml of RPMI-1640. Aliquots of 0.5
ml (typically containing 150–200 mg of explants) were then
added to 3.5 ml of RPMI-1640, in 25-ml polycarbonate
flasks in a shaking water bath. Pulse label was chased for 30
min in the presence or absence of putative effectors of
secretion. This experimental time frame has previously been
shown to allow passage of newly synthesised caseins
through the mammary secretory apparatus [8,21]. The
proportion of newly synthesised caseins secreted into the
extracellular medium and retained in the mammary explant
was assayed and calculated according to the method of
Seddiki and Ollivier-Bousquet [22] as modified by Clegg
et al. [8]. Briefly, explants and incubation medium were
separated by gentle centrifugation. Incubation medium from
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a single incubation was filtered through a 5.0 AM filter
while explants from a single incubation were weighed and
homogenised into 1 ml of 0.2% SDS. Total secreted protein
was then collected from the samples of filtered incubation
media, and total cell-associated protein from the homoge-
nised explants, by TCA precipitation. The precipitates were
separated by SDS-PAGE (15% gels) and the position of the
radiolabeled caseins detected by fluorography. The casein
bands were cut from the gel and quantified by scintillation
counting. For each incubation, the total amount of labelled
precursor incorporated was calculated as Bq/mg of tissue by
summing radioactive protein in the medium and in the
explants. The proportion of protein secreted was then cal-
culated as a fraction of this total.
Using radiolabelled explants from a single rat, experi-
ments were designed such that controls and treatments were
paired and replicated as indicated. For a given experimental
condition, the resulting pairs of values obtained from multi-
ple animals were then compared using Student’s t-test for
paired samples.
2.5. Determination of PDE activities
PDE activity with 1 AM cAMP as substrate was assayed
by a modification of the two-step procedure of Thomson
and Appleman [23] and Rutten et al. [24] as described by
Marchmont and Houslay [25]. The buffer used was 20 mM
Tris/HCl, 10 mM Mg2+ supplemented with 2 mM EGTA
[26]. The effects of Ca2+ /calmodulin (CaM), cGMP and the
PDE inhibitors 3-isobutyl-1-methylxanthine (IBMX),
erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) (a kind gift
from Dr. Podzuweit, Max Planck Institute for Physiology
and Clinical Research, Bad Neuheim, Germany), milrinone,
cilostamide (Calbiochem, Nottingham, UK), and rolipram on
PDE activity were all determined as described previously
[26–28]. The PDE inhibitors IBMX, EHNA, cilostamide
and rolipram were dissolved in 100% DMSO as stock
solutions and diluted in 20 mM Tris/HCl pH 7.4 for use in
the assay. The residual levels of DMSO were shown not to
affect PDE activity at the concentration used in this study.
2.6. Measurement of intracellular cAMP concentrations and
PKA activity in mammary acini
Acini suspensions (30 mg/ml) were prepared as above and
dispensed into 25 ml polycarbonate flasks. These were
incubated for 30 min with shaking in the presence and
absence of putative effectors of intracellular cAMP concen-
trations and PKA activity. Determination of intracellular
cAMP concentrations was as previously published [16] with
the following minor modifications. For each 1 ml sample, the
reaction was stopped using 90 Al of ice-cold 60% perchloric
acid (PCA) (final concentration 5% w/v). All samples were
processed immediately and neutralised by the addition of 5M
KOH containing 0.5M triethanolamine. The concentration of
cAMP in the samples was determined using a competitive
radioligand binding assay [29] using cAMP binding protein
prepared from bovine adrenals. For the determination of A-
kinase activity, 1 ml of the acini suspension was removed
after 15 min incubation to an eppendorf of known weight on
ice and spun for 15 s at 1000 g in a refrigerated microfuge.
The supernatant was removed, the weight of acini determined
and the samples snap frozen in liquid nitrogen. Samples were
then stored at  70 jC until determination of the A-kinase
activation ratio. Extracts for the assay of A-kinase were
prepared as described by Clegg and Ottey [30] and the A-
kinase activity measured as previously [30,31].
2.7. Isolation of total RNA from mammary tissue
Total cellular RNA was isolated from mammary gland
tissue using guanidinium isothiocyanate (Melford Laborato-
ries, Ipswich, Suffolk, UK), and CsCl centrifugation [32].
All preparations of RNAwere resuspended in water and their
RNA concentration determined according to UVabsorbance
measured at 260 nm. All preparations were assessed qual-
itatively on a 1.2% formaldehyde agarose gel [33].
2.8. RtPCR
RtPCR was performed using the Access RT-PCR system
from Promega according to manufacturer’s instructions.
Reactions routinely contained 1 Ag of mammary RNA and
50 pmol of both upstream and downstream primer. Primers
were designed as previously described [34] and supplied by
Cruachem (Glasgow, Scotland, UK). Negative controls were
prepared by replacing the RNA template with nuclease-free
water, according to the manufacturer’s instructions. Positive
controls were performed using RNA from tissue known to
express the cAMP-PDE isozyme being investigated. Reac-
tion products were resolved by electrophoresis on a 1.5%
agarose gel and visualised with ethidium bromide under UV
light.
3. Results
3.1. Inhibition of cAMP-PDE activity stimulates the rate of
cAMP-induced casein secretion in rat mammary explants
To assess the influence of cAMP-PDE activity on casein
secretion, putative effectors of the cAMP system were added
immediately after the pulse labelling of explants and cumu-
lative casein secretion measured following the subsequent 30
min period of incubation (see Materials and methods). The
results are shown in Table 1.
Freshly prepared rat mammary explants typically se-
creted about 20% of newly synthesised casein within the
30 min time course of the experiment. General inhibition of
cAMP-PDE activity by IBMX failed to increase the amount
of casein secreted. However, general inhibition of cAMP-
PDE activity did increase the rate of cAMP-stimulated
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casein secretion. Casein secretion could be stimulated using
the cAMP-elevating agent forskolin. General inhibition of
cAMP-PDE activity in the presence of 10 AM forskolin
significantly increased the rate of secretion further com-
pared to forskolin-treated alone. This data supports the
hypothesis that cAMP-PDE activity negatively regulates
cAMP-stimulated casein secretion. DMSO, which was used
to solubilise forskolin, had no effect on the rate of casein
secretion at the concentrations used in these experiments
(data not shown).
3.2. Rat mammary gland expresses type II, type III and type
IV cAMP-PDE activity
The cAMP-PDE activities expressed in the rat mammary
gland (Table 2) were determined using experimental
approaches previously described [26–28].
PDE1 activity can be selectively stimulated by the addi-
tion of calcium and CaM [35]. In these experiments, no
increase in the total PDE activity of the homogenate was
detected when calcium and CaM were included in the assay,
indicating that PDE1 enzyme activity could not be detected
in homogenates of rat mammary explants. PDE2 activity can
be selectively inhibited by the compound EHNA (10 AM).
[36], with maximum inhibition being achieved in the pres-
ence of maximally stimulating concentrations of cGMP [28].
In both the presence and absence of cGMP, approximately
17% of the total PDE activity of the rat mammary gland
homogenate was inhibited by this compound. The PDE3
selective inhibitors, cilostamide (5 AM) and milrinone (5
AM) [37], were used to gauge the magnitude of PDE3
activity and showed that about 13% of the total activity
could be attributed to type III activity. Rolipram (10 AM), a
PDE4-selective inhibitor [9] inhibited some 70% of the total
cAMP-PDE activity.
In experiments using 100 AM IBMX, only 82.1F 0.1%
inhibition of cAMP-PDE activity was observed, suggesting
that a small amount of PDE7 or PDE8 activity may be
present [26,38,39]. As there are no specific inhibitors avail-
able for these two families, quantification of their activity is
difficult. However, given that the combined activities of the
types II, III and IV PDEs (26, 20.5 and 102 pmol/min/mg,
respectively) equates with the total measured activity
(144F 14 pmol/min/mg), and that the simultaneous inhib-
ition of type II, III and IV PDEs using EHNA, milrinone and
rolipram caused inhibition of a magnitude similar to that seen
using 1 mM IBMX, it was assumed that any contribution of
PDE7 or PDE8 activity to mammary gland cAMP-PDE
activity is negligible. Furthermore, for the purpose of this
study, the effects of general PDE inhibition on the rate of
casein secretion can be completely mimicked by inhibition
of PDE4 activity using rolipram at concentrations that do not
inhibit PDE7 or PDE8 activity [38,39] (see later). Therefore,
it was taken that any PDE7 or PDE8 activity has no effect on
casein secretion. Consequently, the possibility of their
expression in the mammary gland was not explored further.
Table 1
Effect of general cAMP-PDE inhibition on the rate of casein secretion from
lactating rat mammary explants
Treatment Effect Percent casein
secreted (%)
No additions Control 20.91F1.40
1 mM IBMX General inhibition of
cAMP-PDE activity
18.55F 2.19
10 AM Forskolin Elevation of intracellular
cAMP levels
23.73F 0.83*
10 AM Forskolin
and 1 mM IBMX
Elevation of intracellular
cAMP levels and general
inhibition of cAMP-PDE activity
26.6F 0.95 * ,y
Casein secretion was measured as described in Materials and methods.
General cAMP-PDE inhibition using 1 mM IBMX had no effect on casein
secretion. Forskolin significantly ( P < 0.01) increased the rate of casein
secretion compared to control, untreated samples (data from six separate
animals: three experimental replicates per animal). General cAMP-PDE
inhibition significantly increased the effects seen using forskolin ( P< 0.01).
Data from 15 separate animals (three replicates per animal) was shown to be
significant by both paired Student’s t-test and ANOVA. All data is
presented as the mean (F S.E.) rate of casein secretion.
* Denotes values that differ significantly from control.
y Denotes values that differ significantly from all others.
Table 2
Effect of selective PDE inhibitors and activators on PDE activity of
mammary gland explants taken from rats at mid-lactation
Treatment Activity
determined
Calculated
PDE activity
No additions Total 144.3F 14.0
Ca2+ /CaM-stimulated
component
Type I not detected
EHNA-inhibited
component
Type II 25.6F 5.8
Cilostamide-inhibited
component
Type III 21.4F 8.1
Milrinone-inhibited
component
Type III 19.4F 6.7
Rolipram inhibited
component
Type IV 102.2F 11.4
IBMX (1 mM)-inhibited
component
135.8F 14.1
IBMX (100 AM)-inhibited
component
116.1F11.8
EHNA+milrinone + rolipram-
inhibited component
133.5F 0.87
Mammary explants were harvested as described in Materials and methods.
Explants (approximately 100 mg) were homogenised into 1 ml 20 mM Tris/
HCl pH 7.4 containing protease inhibitors by three 5-s bursts of an Ultra-
Turrax T25 homogeniser (Scientific Laboratory Supplies, Nottingham,
UK). Cellular debris was removed by centrifugation at 1000 g for 5 min
at 4 jC. The supernatant was removed and designated ‘‘homogenate’’. Total
activity was determined using 1 AM cAMP as substrate with no additions.
Type II activity (EHNA-inhibited component) was calculated as the
difference between this total activity and the activity measured in samples
treated with EHNA. Similarly, Type III and Type IV activities were
calculated as the difference in measured activity between this total activity
and samples treated with cilostamide/milrinone and rolipram, respectively.
All activities are expressed as pmol cAMP hydrolysed/min/mg homogenate
and shown as the meanF S.E.
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3.3. Type IV cAMP-PDE activity specifically regulates casein
secretion
Specific inhibitors were used to assess the relative con-
tribution of each individual cAMP-PDE family to the control
of cAMP-stimulated casein secretion. For each individual
inhibitor, cumulative forskolin-stimulated casein secretion in
the presence of the inhibitor was compared to the cumulative
casein secretion from explants treated with forskolin alone.
The results (Table 3) are expressed as previously [8] as the
rate of secretion in the presence of the inhibitor relative to
casein secretion in the presence of 10 AM forskolin only,
which is arbitrarily set as being 100%.
The type II PDE inhibitor, EHNA (10 AM), had no effect
on the rate of forskolin-stimulated casein secretion. Although
a slight increase in the average rate of casein secretion
relative to that seen using 10 AM forskolin alone was
observed, this rise was not statistically significant. The
influence of type III cAMP-PDE activity in the rat mammary
gland was similarly assessed using 10 AM milrinone. Again,
no significant increase in the rate of forskolin-stimulated
casein secretion was observed. Indeed, even when 10 AM
EHNA and 10 AM milrinone were administered simultane-
ously, together inhibiting about one third of the total cAMP-
PDE activity in the mammary explants, still no significant
increase in the rate of forskolin-stimulated casein secretion
could be detected. Specific inhibition of the Type IV cAMP-
PDE activity by rolipram [10 AM] in the presence of
forskolin increased casein secretion by a significant amount
compared to that seen using just forskolin. The rate of
forskolin-stimulated secretion in the presence of rolipram
Table 3
Effect of selective PDE inhibitors on the rate of forskolin-stimulated casein
secretion from rat mammary explants
Treatment Relative rate of
casein secretion
10 AM Forskolin 100a
10 AM Forskolin + 1 mM IBMX 116.7F 4.1b
10 AM Forskolin + 10 AM EHNA 104F 3.4a
10 AM Forskolin + 10 AM milrinone 104F 5.0a
10 AM Forskolin + 10 AM milrinone
and 10 AM EHNA
99.87F 8.4a
10 AM Forskolin + 10 AM rolipram 122F 10.7b
Casein secretion was measured as described in Materials and methods. The
mean rate of casein secretion is expressed as a percentage relative to that
seen in explants (F S.E.) treated with 10 AM forskolin, which is arbitrarily
set as being 100%. The data shown is from at least three separate animals.
For each animal, four paired experimental samples were analysed for each
of the conditions. Values with different superscript differ significantly
( P< 0.05) from each other.
Table 4
Effect of PKA- and transcriptional-inhibition on the rate of casein secretion
Treatment Relative rate of
casein secretion
10 AM Forskolin/10 AM rolipram 100
10 AM Forskolin/10 AM rolipram/
10 AM myrPKI
89.5F 7.3*
10 AM forskolin/10 AM rolipram/
800 nM actinomycin-D
106.7F 6.6
Casein secretion was measured as described in Materials and methods. The
rate of casein secretion is expressed as a percentage (meanF S.E.) relative
to that seen in samples treated with 10 AM forskolin and 10 AM rolipram,
which is arbitrarily set as being 100%. The data shown is from four separate
animals. For each animal, at least three paired experimental samples were
analysed for each of the conditions.
Control (untreated) samples were also included in these experiments and
confirmed that forskolin and rolipram increased casein secretion relative to
untreated samples by 126.4F 8.8% (data not shown).
* Values that differ significantly ( P< 0.05).
Fig. 1. Accumulation of intracellular cAMP in rat mammary acini by
effectors of the cAMP signalling system and cAMP-PDE selective
inhibitors. Mammary acini were prepared and treated as described in
Materials and methods. The data shown is from three separate animals.
Each sample was assayed in triplicate. All graphs show intracellular cAMP
accumulation as pmol cAMP/g wet weight acini (meanF S.E.) as a
function of the time of treatment. In panel a, 5 represents control
(untreated) acini. In all panels, n represents acini treated with 10 AM
forskolin alone and . acini treated with 10 AM forskolin and 1 mM IBMX.
In all panels, E represents acini treated with 10 AM forskolin and the
selective PDE inhibitor(s). These are rolipram (panel a), EHNA (panel b),
milrinone (panel c) and EHNA with milrinone (panel d).
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was the same as that seen in the presence of the general PDE
inhibitor IBMX. These results suggest that in mammary
epithelial cells, the rate of cAMP-stimulated casein secretion
is specifically regulated by type IV cAMP-PDE activity.
3.4. Regulation of casein secretion by type IV cAMP-PDE is
accompanied by specific changes in intracellular cAMP and
activation of PKA but does not require ongoing
transcription
Stimulation of casein secretion by forskolin and rolipram
was significantly reduced by the cell-permeant PKA inhib-
itor myr PKI (a kind gift from Dr. Clegg, Hannah Research
Institute, Scotland, UK) [8] (see Table 4). It was thought,
therefore, that cAMP-PDE activity may affect casein secre-
tion by regulating intracellular levels of cAMP and PKA
activation in the secretory epithelial cells and this possibility
was explored in acini. Acini were chosen for this exper-
imental work as they are enriched in the secretory epithelial
cells, making measurement of changes in cAMP more easily
detectable.
The increase in the rate of forskolin-stimulated casein
secretion by application of the general PDE inhibitor IBMX
was accompanied by a rapid increase in the accumulation of
intracellular cAMP to some five-fold higher than that seen
in acini treated with forskolin alone (Fig. 1a). An increase of
similar magnitude compared to forskolin treatment alone
could be seen using the PDE4 specific inhibitor rolipram.
Again, this increase was observed within 5 min of applica-
tion (Fig. 1a). In contrast, application of the PDE2-selective
inhibitor EHNA with forskolin caused a slower accumula-
tion of intracellular cAMP (Fig. 1b). The maximum increase
in intracellular cAMP levels that could be achieved using
EHNA was just 1.5-fold over a period of 30 min. Inhibition
of PDE3 activity using milrinone caused only a very small
increase in the levels of intracellular cAMP over and above
those achieved using only forskolin (Fig. 1c). Concurrent
administration of EHNA and milrinone with forskolin in-
creased cAMP some two-fold (Fig. 1d).
The increases in intracellular cAMP levels were mirrored
by alterations in the PKA activation ratio in mammary acini
(Table 5). By itself, forskolin caused just a two-fold increase
in the PKA activation ratio whereas the inclusion of IBMX
with forskolin brought about an increase of some seven-fold.
The PKA activation ratio elicited by forskolin could also be
increased by inhibition of each of the cAMP-PDE families.
The maximum increase in the PKA activation ratio (five-
fold) was seen in acini in which PDE4 activity was inhibited
(acini treated with forskolin and rolipram). In comparison,
the maximum stimulation achieved by inhibition of both
PDE2 and PDE3 together was just some three-fold and indi-
vidually, these PDE families had even less effect on the PKA
activation ratio.
PKA elicits a cellular response by phosphorylating target
substrate molecules. A possible target of PKA action in this
system would be an increase in gene transcription by the
translocation of PKA to the nucleus and its binding to CREB/
CREM sites. To see if such a mechanism was involved in the
cAMP-stimulation of casein secretion, the need for ongoing
Table 5
PKA activation ratio in mammary acini treated with effectors of the cAMP
signalling pathway
Treatment Activity ratio
Control (untreated) 0.049F 0.011
10 AM Forskolin 0.098F 0.013
10 AM Forskolin + 1 AM IBMX 0.341F 0.023
10 AM Forskolin + 10 AM EHNA 0.161F 0.031
10 AM Forskolin + 10 AM milrinone 0.123F 0.034
10 AM Forskolin + 10 AM EHNA+10 AM milrinone 0.171F 0.016
10 AM Forskolin + 10 AM rolipram 0.251F 0.014
Mammary acini were prepared and treated as described in Materials and
methods. The results shown are from three separate animals. For each
treatment, three separate determinations were made. All data are presented
as meanF S.E.
Fig. 2. Detection of PDE4 family gene products by RtPCR. RNA was
prepared from lactating rat mammary tissue and probed for the expression
of the four known gene families, 4A, 4B, 4C and 4D of the type IV cAMP-
PDEs by RtPCR as described in Materials and methods. Reaction products
were resolved by electrophoresis on a 1.5% agarose gel and visualised with
ethidium bromide under UV light. Primers specific for each gene family
were as previously described [36]. Each panel shows: lane 1, positive
control (+); lane 2 negative control () (no RNA); lanes 3, 4 and 5 (L10),
day 10 lactating rat mammary tissue from three separate animals. The
positive controls for 4A, 4B and 4D were performed using RNA prepared
from rat brain [34] and for 4C, RNA prepared from 3T3-F442A cells [44].
The results shown are typical of three separate reactions for each condition.
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transcription in this system was investigated. Casein secre-
tion from rat mammary explants was measured as previously
described in both control (untreated) samples and samples
stimulated to increase their rate of casein secretion by the
addition of forskolin and rolipram. Transcription was
inhibited by the inclusion of 800 nM actinomycin-D (con-
centrations previously shown to inhibit transcription in mam-
mary explants) [40]. Inhibition of transcription had no effect
on the rate of casein secretion (Table 4). This suggests that
CREB is not the target of PKA activity in the regulation of
casein secretion.
3.5. Rat mammary gland specifically expresses three
isozymes of the PDE4 family: RNPDE4A5, RNPDE4A8 and
RNPDE4D3
The type 4 family of PDEs is encoded by four separate
genes, 4A, 4B, 4C and 4D. Within each of these families,
alternative splicing gives rise to multiple isoforms. To assess
which members of the type 4 family are expressed in the rat
mammary gland and hence which isozymes may regulate
casein secretion, RtPCR studies were undertaken as previ-
ously described [36]. Of the four genes known to be expres-
sed in this family, transcripts for only two, 4A and 4D, were
detected. No transcripts could be found for either the 4B or
4C families (Fig. 2). In the rat, the 4A gene encodes at least
three different splice products RNPDE4A1, RNPDE4A5 and
RNPDE4A8 [41] and the 4D gene five different products,
RNPDE4D1, RNPDE4D2, RNPDE4D3, RNPDE4D4 and
RNPDE4D5 [42]. Using available genetic sequences and
splice-variant-specific primers, only transcripts for two of the
4A splice variants RNPDE4A5 and RNPDE4A8 could be
detected. Using the genetic sequences available for the rat
PDE4D splice variants, only RNPDE4D3 could be detected
(Fig. 3). To the author’s knowledge, this data represents the
first full characterisation of the type IV cAMP-PDE isozymes
expressed in lactating rat mammary tissue.
4. Discussion
This study clearly demonstrates that cAMP-PDE activity
negatively regulates the rate of constitutive casein secretion
in lactating rat mammary gland. Most interestingly, although
the gland contains multiple forms of cAMP-PDE activity,
the effects on casein secretion are specifically modulated by
PDEIV. This data demonstrates for the first time, a potential
physiological role for cAMP phosphodiesterase activity in
the mammary gland. Furthermore, it adds to the growing
body of evidence that individual PDE activities perform
specific cellular functions. The biochemical and RtPCR data
reported represents the first complete characterisation of the
cAMP-PDE isozymes of the lactating rat mammary gland.
Previous work has suggested that PKA activity is
required to maintain basal levels of constitutive casein
secretion [8]. Perturbations of PKA activity act to regulate
the rate of casein secretion such that inhibition of PKA
decreases secretion whereas elevation of cAMP, and hence
PKA activity, increases the rate of secretion. The data
presented here confirms these observations and extends
them showing that the cAMP-PDE activity of mammary
cells also contributes to the regulation of the system. The
data suggests that cAMP-PDE activity constrains the extent
of PKA activation, and hence in vivo, may limit the amount
by which casein secretion can be increased using this
signalling pathway.
The relative importance of this regulation in vivo remains
to be determined. Previously, much consideration has been
given to the calcium-regulated, triggered release of casein
[2]. However, given that milk protein secretion is considered
largely constitutive rather than triggered, any potential
mechanisms of regulation of the Ca2+ -independent, basal-
constitutive pathway are of interest. Evidence presented
here, coupled with previous findings [8], indicate that the
cAMP-signalling pathway may be important in this respect.
Physiologically, this pathway may contribute to the mech-
anisms used by the mother to control milk output.
The cAMP-PDE activity specifically affects cAMP-
stimulated casein secretion. The failure of general cAMP-
PDE inhibition in the absence of a cAMP-elevating agent to
affect casein secretion may be due to the inability of IBMX
by itself to significantly increase levels of intracellular
Fig. 3. Detection of PDE4 splice variants by RtPCR. RNA was prepared
from lactating mammary tissue and probed for the expression of the known
splice variants of the PDE4 gene families, 4A and 4D by RtPCR as
described in Materials and methods. Reaction products were resolved by
electrophoresis on a 1.5% agarose gel and visualised with ethidium bromide
under UV light. Primers specific for each splice variant were as previously
described [36]. Each panel shows: lane 1, positive control (+); lane 2,
negative control () (no RNA); lanes 3, 4 and 5 (L10), day 10 lactating rat
mammary tissue from three separate animals. The positive controls for 4A5
and 4D3 were performed using RNA prepared from rat brain [42,43] and
for 4A8 using RNA prepared from rat testes [41]. The results shown are
typical of three separate reactions for each condition.
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cAMP in mammary cells (as previously shown [16]).
Similar effects have been well-documented in hepatocytes
(as summarised in Ref. [10]). In hepatocytes, inhibition of
cAMP-PDE activity in the absence of additional effectors
has no effect on the activity of PKA (attributable to a low
basal level of adenylate cyclase activity). However, once
adenylate cyclase and PKA are activated, cAMP-PDE
activity can have a profound influence on the magnitude
and duration of that activation [10]. Previous data [16] and
observations made here suggest the same scenario is also
apparently true in mammary epithelial cells. The nature and
activity of the adenylate cyclase forms expressed in the
mammary gland has not been fully explored or reported.
The lactating rat mammary gland is shown to express just
three cAMP-PDE activities, type II, III and IV. The type II
and type IV activity measured represents that previoulsy
reported [14]. Using selective inhibitors the presence of a
third activity, PDE3 is confirmed. Type III PDE activity can
be stimulated by insulin [11] and this PDE is presumably the
target of the insulin effects in mammary acini previously
reported by Aitchison et al. [15]. A fuller investigation of
the type IV activity using RtPCR showed just three type IV
isozymes, RNPDE4A5, RNPDE4A8 and RNPDE4D3 are
expressed. The apparent expression of RNPDE4A8 is par-
ticularly noteworthy as it was previously thought that this
isoform was expressed predominantly if not exclusively in
testes [43]. Notably though, in that paper, the authors did
not screen lactating mammary tissue. Together these results
present the fullest characterisation of cAMP-PDE activity of
lactating mammary gland to date.
Given the number of cAMP-PDE activities in the gland, it
is particularly interesting that casein secretion is specifically
regulated by type IVactivity. Clearly, the type IVactivity has
the most profound effect on intracellular cAMP levels. In
addition, considering the PKA activation ratio data, although
inhibition of PDE4 does not achieve the same magnitude of
activation seen using IBMX, it has a far greater influence
than PDE2 and PDE3 activities. These differences may
possibly partly explain the specific regulation of casein
secretion by PDE4 activity. However, although inhibition
of PDE2 and PDE3 do not affect cAMP and PKA to the same
extent as PDE4, both do have some influence on these
parameters. Why then, do they not affect casein secretion?
It is hypothesised that the coordination in both space and
time of the components of the cAMP signalling system
allows the cell to generate compartmentalised cAMP
responses within a single cell [10]. This results in localised
concentration gradients of cAMP and specific pools of PKA
activity. Depending upon their location and activity within
the cell, individual PDE activities may regulate the different
pools of cAMP and PKA. In this context, it is worth noting
that the isozymes expressed in the rat mammary gland have
previously been shown to be able to be targeted to specific
intracellular locations [41–43]. Such targeting gives them
the potential to participate in compartmentalised intracellular
responses to cAMP as discussed. Also critical to this model
is the location of the downstream target of PKA. It has
previously been suggested that a phosphorylation event,
possibly associated with the Golgi apparatus, may be impor-
tant in the PKA-mediated regulation of casein secretion [8].
The finding that ongoing transcription is not required for
PKA-mediated increases in casein secretion lends weight to
the hypothesis that a phosphorylation event is critical in this
process.
Using compartmentalisation as a working model, the data
presented here would suggest that PDE4 activity influences
the pool of cAMP and PKA activity associated with casein
secretion but that PDE2 and PDE3 activities do not. Further
work to characterise the subcellular localisations of the
components of the cAMP-signalling system and the nature
and location of the target of PKA phosphorylation may
support this hypothesis. It may also provide an insight into
which individual isoforms are involved in the regulation of
casein secretion. In this respect, the role of PDE4D3 would
be particularly interesting as this isozyme has previously
been implicated in the negative regulation of secretory
processes [12]. Unfortunately, such questions could not be
addressed using the methods employed in this study, as no
gene-family specific inhibitors are yet available. Similarly,
an antisense-approach to specifically ablate one activity
could not be applied to this system as the tissue and secretory
activity can only be maintained for a short time in culture.
Indeed, no robust, transfectable, cell system that secretes
casein at physiological levels exists. The development of
such an in vitro system would greatly aid such experiments
and also allow for real-time intracellular imaging of key
components of the cAMP-signalling system.
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